Summary of the technology
OLD: New Nasal Delivery Technology for Quick-Onset Treatment such as Insomnia, Erectile Difunction, Pain, Hot Flashes and Other
Project ID : 6-2009-2237
Description of the technology
CNS (MS, Insomnia, Sleepiness, Emesis, Parkinson), Hyperglycemias,
Hot Flushes, Obesity
Drug delivery, Novel Carrier
Concept has been proved in animal models (including sheep) for manydiseasesand various drugs including large molecules and peptides. Industrial upscale results.
Patents filed in United States, Europe, Japan, Israel, India and China; published in the United States, Europe and Japan
With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs including peptides..
- Technology for efficient drug therapy by nasal delivery
- Wide number of experiments in animal models
- Examples: very efficient treatment and disease prevention in EAE mice (drugs: steroids, glatiramer acetate, new drug combinations), antiemetic in rat model (drug: granisetron),antiwrithing effect (drug: diazepam), malaria prevention and treatment ( drug: DHA), insomnia (drugs: benzodiazepine, melatonin, antihistamines ), obesity (drug: insulin, others) Parkinsonrotational model (drug: apomorphine),
- Platform drug delivery carrier technology for approved or new drugs, single drugs or combination of drugs (also including new drug combinations).
- Improved delivery into the brain
- Better bioavailability by nasal route than by oral or subcutaneous routes
- Particularly important in crisis management such as for multiple sclerosis, Alzheimer, insomnia, glioma, sleepiness (EDS), epileptic seizures, hyperglycemia, hypoglycaemia, hot flushes, emesis, Parkinson rigidity
- Carrier ingredients already have FDA approval for nasal delivery
- Increase patient compliance - needle-free alternative for delivering drugs for acute and chronic conditions, allowing self-medication
- Proof of concept achieved in animal models
- Planned Phase I and Phase II trials
- Seeking investment and cooperation for ongoing development of a number of drugs
- Prior FDA ingredient approvals will lead to faster product approval process